Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Oncology Inc. (NasdaqGS: RAIN) is a clinical-stage biotechnology company developing precision therapies targeting specific cancer drivers. This news hub provides investors and researchers with timely updates on the company's progress in oncology innovation, including its lead candidate milademetan and strategic initiatives.
Access authoritative updates on clinical trial developments, regulatory milestones, and corporate announcements. The resource consolidates essential information about RAIN's therapeutic pipeline, financial position, and partnership activities – critical data points for evaluating the company's trajectory in precision medicine.
Key coverage areas include progress in Phase 3 MANTRA trials for liposarcoma, updates on tumor-agnostic basket studies, and analysis of strategic merger plans with Pathos AI. All content maintains rigorous standards for accuracy and clarity, serving both professional investors and those monitoring advancements in cancer treatment.
Bookmark this page for direct access to verified Rain Oncology announcements and objective reporting on developments impacting the company's scientific and financial progress.
Rain Oncology Inc. (NASDAQ: RAIN) announced that it will report its first quarter financial results for the period ending March 31, 2023, along with updates on its business on May 11, 2023. The company is focused on developing precision oncology therapeutics, particularly its lead candidate, milademetan, which inhibits the MDM2-p53 complex to reactivate p53. A conference call and webcast will follow the earnings release, scheduled for 2:00 PM PT (5:00 PM ET) on the same day. Investors can access the call via phone or through the provided webcast link. Rain's strategy involves a tumor-agnostic approach, selecting patients based on tumor genetics.
Rain Oncology Inc. (NasdaqGS: RAIN) announced a poster presentation at the upcoming AACR Annual Meeting 2023, scheduled from April 14-19 in Orlando, Florida. The poster, presented by Dr. Arielle Elkrief from Memorial Sloan Kettering Cancer Center, focuses on MDM2 inhibition and MEK inhibition in preclinical models of lung adenocarcinomas. The presentation, titled “MDM2 inhibition in combination with MEK inhibition in preclinical models of lung adenocarcinomas with MDM2 amplification”, is set for April 19 at 9:00 A.M. ET. The details will be accessible on Rain's website post-presentation.
Rain Oncology Inc. (RAIN) has announced that its abstract on milademetan, an oral MDM2-p53 inhibitor, will be presented at the 2023 ESMO Sarcoma and Rare Cancers Annual Congress in Lugano, Switzerland. The presentation, titled "MDM2 inhibitor milademetan: safety profile and management of adverse events (AEs)", will take place on March 21, 2023, at 10:50 AM CET. This event underscores the company's commitment to developing precision oncology therapies that target oncogenic drivers. Milademetan aims to reactivate p53, and further materials from the presentation will be available on the Rain website after the event.
Rain Oncology Inc. (NASDAQ: RAIN) reported financial results for Q4 and full year 2022, showing a net loss of $22.7 million for the quarter and $75.7 million for the year. The company ended 2022 with $130.5 million in cash, sufficient for ongoing clinical trials of milademetan, including the Phase 3 MANTRA trial with expected topline data in Q2 2023. R&D expenses rose significantly to $19.1 million for Q4 and $61.4 million for the year, driven by clinical trial costs. Rain anticipates filing for regulatory approvals in the U.S. and Europe if supportive data is generated.
FAQ
What is the current stock price of Rain Enhancement (RAIN)?
What is the market cap of Rain Enhancement (RAIN)?
